Humanigen Inc (HGENQ)

[Fezziwig2008]

On HGEN- “After the SARS-CoV-2 infection, CD4+ T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate GM-CSF etc. The cytokines environment induces inflammatory CD14+CD16+ monocytes with high expression of IL-6 and accelerate the inflammation. Given that large amount of inflammatory cells infiltrations have been observed in lungs from severe COVID-19 patients7, 8, these aberrant pathogenic Th1 cells and inflammatory monocytes may enter the pulmonary circulation in huge numbers and play an immune damaging role to causing lung functional disability and quick mortality. Our results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology. Thus, we suggest that monoclonal antibodies targeting GM-CSF may be effective in blocking inflammatory storms and, therefore, be a promising treatment of severe COVID-19 patients“



https://scholar.google.com.hk/scholar?as_ylo=2019&q=GM+CSF+COVID+19&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3Dip5xng9X7KwJ